

<b>Reference:</b>	FOI.6253.21
<b>Subject:</b>	Cancer treatments
<b>Date of Request:</b>	16 June 2021

**Requested:**

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
  - Avelumab + Axitinib
  - Axitinib
  - Cabozantinib
  - Everolimus
  - Lenvantinib + Everolimus
  - Nivolumab
  - Nivolumab + Ipilimumab
  - Pazopanib
  - Pembrolizumab + Axitinib
  - Sunitinib
  - Temsirolimus
  - Tivozanib
  - Other
  
2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
  - Cobimetinib
  - Dabrafenib
  - Dabrafenib + Trametinib
  - Encorafenib + Binimetinib
  - Ipilimumab
  - Ipilimumab + Nivolumab
  - Nivolumab
  - Pembrolizumab
  - Trametinib
  - Vemurafenib
  - Vemurafenib + Cobimetinib
  - Other active systemic anti-cancer therapy
  - Palliative care only
  
3. If possible, could you please provide the patients treated in the past 3 months with the following agents for **metastatic melanoma ONLY**:
  - Cobimetinib
  - Dabrafenib
  - Dabrafenib + Trametinib
  - Encorafenib + Binimetinib
  - Ipilimumab
  - Ipilimumab + Nivolumab
  - Nivolumab

- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib + Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

**Response:**

This information is already within the public domain; therefore, Hywel Dda University Health Board (UHB) has applied an Exemption under Section 21 of the Freedom of Information Act 2000 (FoIA), as the information is accessible by another means. The UHB has answered a similar Freedom of Information request, FOI/4171/20, which is available on our disclosure log.

For ease of reference, please click on the attached link, which will take you directly to the UHB's disclosure log webpage:

<https://hduhb.nhs.wales/about-us/governance-arrangements/freedom-of-information/disclosure-log/>